Lyra Therapeutics LYRA Stock
Lyra Therapeutics Price Chart
Lyra Therapeutics LYRA Financial and Trading Overview
| Lyra Therapeutics stock price | 0.7 USD |
| Previous Close | 0.74 USD |
| Open | 0.7 USD |
| Bid | 0.71 USD x 296700 |
| Ask | 0.75 USD x 129800 |
| Day's Range | 0.7 - 0.75 USD |
| 52 Week Range | 0.31 - 34 USD |
| Volume | 1.69K USD |
| Avg. Volume | 37.76K USD |
| Market Cap | 1.24M USD |
| Beta (5Y Monthly) | 0.688 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -18.62 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
LYRA Valuation Measures
| Enterprise Value | 15.61M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.7070707 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.1216507 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 39.217 |
| Enterprise Value/EBITDA | -0.536 |
Trading Information
Lyra Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.688 |
| 52-Week Change | -97.46% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 34 USD |
| 52 Week Low | 0.31 USD |
| 50-Day Moving Average | 0.66 USD |
| 200-Day Moving Average | 3.16 USD |
LYRA Share Statistics
| Avg. Volume (3 month) | 37.76K USD |
| Avg. Daily Volume (10-Days) | 6K USD |
| Shares Outstanding | 1.77M |
| Float | 336.13K |
| Short Ratio | 0.35 |
| % Held by Insiders | 0.61% |
| % Held by Institutions | 13.25% |
| Shares Short | 16.53K |
| Short % of Float | 1.09% |
| Short % of Shares Outstanding | 0.92% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:50 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -98728.57% |
| Gross Margin | -152.76% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -36.055% |
| Return on Equity (ttm) | -6594.98% |
Income Statement
| Revenue (ttm) | 398K USD |
| Revenue Per Share (ttm) | 0.26 USD |
| Quarterly Revenue Growth (yoy) | -96.70% |
| Gross Profit (ttm) | -608000 USD |
| EBITDA | -29094000 USD |
| Net Income Avi to Common (ttm) | -28919000 USD |
| Diluted EPS (ttm) | -18.62 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 15.89M USD |
| Total Cash Per Share (mrq) | 8.95 USD |
| Total Debt (mrq) | 30.26M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.709 |
| Book Value Per Share (mrq) | -6.038 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -28859000 USD |
| Levered Free Cash Flow (ttm) | -17529624 USD |
Profile of Lyra Therapeutics
| Country | United States |
| State | MA |
| City | Watertown |
| Address | 480 Arsenal Way |
| ZIP | 02472 |
| Phone | 617 393 4600 |
| Website | https://lyratherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 27 |
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Q&A For Lyra Therapeutics Stock
What is a current LYRA stock price?
Lyra Therapeutics LYRA stock price today per share is 0.7 USD.
How to purchase Lyra Therapeutics stock?
You can buy LYRA shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lyra Therapeutics?
The stock symbol or ticker of Lyra Therapeutics is LYRA.
Which industry does the Lyra Therapeutics company belong to?
The Lyra Therapeutics industry is Biotechnology.
How many shares does Lyra Therapeutics have in circulation?
The max supply of Lyra Therapeutics shares is 1.77M.
What is Lyra Therapeutics Price to Earnings Ratio (PE Ratio)?
Lyra Therapeutics PE Ratio is now.
What was Lyra Therapeutics earnings per share over the trailing 12 months (TTM)?
Lyra Therapeutics EPS is -18.62 USD over the trailing 12 months.
Which sector does the Lyra Therapeutics company belong to?
The Lyra Therapeutics sector is Healthcare.
Lyra Therapeutics LYRA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26761.07 USD — |
-0.35
|
4.06B USD — | 26554.24 USD — | 26812.16 USD — | — - | 4.06B USD — |
| US Tech Global Market Composite NQGM | 2331.53 USD — |
+1.55
|
— — | 2280.63 USD — | 2342.75 USD — | — - | — — |
| US Tech Health Care IXHC | 1159.84 USD — |
+2.32
|
— — | 1146.48 USD — | 1165.81 USD — | — - | — — |
- {{ link.label }} {{link}}